Literature DB >> 15618964

New insight into the molecular mechanisms of MLL-associated leukemia.

Z-Y Li1, D-P Liu, C-C Liang.   

Abstract

Rearrangements of the MLL gene (ALL1, HRX, and Hrtx) located at chromosome band 11q23 are commonly involved in adult and pediatric cases of primary acute leukemias and also found in cases of therapy-related secondary leukemias. Studies on mouse models of MLL translocation and cell lines containing MLL rearrangements showed that the MLL gene linked chromosomal rearrangements to cellular differentiation and tumor tropism. Moreover, recent structural/functional studies on MLL and aberrant MLL proteins provided new clues and suggested that different mechanisms might be included in leukemogenesis by MLL rearrangements. The connection between these different mechanisms will help us understand globally how aberrant MLL oncogenes affect the normal cellular processes at molecular level.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15618964     DOI: 10.1038/sj.leu.2403602

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

1.  Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.

Authors:  Eric Schafer; Rafael Irizarry; Sandeep Negi; Emily McIntyre; Donald Small; Maria E Figueroa; Ari Melnick; Patrick Brown
Journal:  Blood       Date:  2010-03-09       Impact factor: 22.113

Review 2.  Molecular diagnosis and risk-adjusted therapy in pediatric hematologic malignancies: a primer for pediatricians.

Authors:  Judith Frances Margolin
Journal:  Eur J Pediatr       Date:  2011-02-25       Impact factor: 3.183

3.  Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.

Authors:  Jennifer Richmond; Hernan Carol; Kathryn Evans; Laura High; Agnes Mendomo; Alissa Robbins; Claus Meyer; Nicola C Venn; Rolf Marschalek; Michelle Henderson; Rosemary Sutton; Raushan T Kurmasheva; Ursula R Kees; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2015-01-08       Impact factor: 12.531

4.  MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures.

Authors:  Andrea Zangrando; Marta Campo Dell'orto; Geertruy Te Kronnie; Giuseppe Basso
Journal:  BMC Med Genomics       Date:  2009-06-23       Impact factor: 3.063

5.  11q23 abnormalities in adult Chinese patients with hematological malignancies.

Authors:  Xiaoli Zhao; Shuang Li; Nianyi Li; Rong Fan; Guowei Lin; Xiaoqin Wang
Journal:  Med Oncol       Date:  2014-07-10       Impact factor: 3.064

Review 6.  Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia.

Authors:  J Yang; A Bogni; C Cheng; W K Bleibel; X Cai; Y Fan; W Yang; J C C Rocha; D Pei; W Liu; M E Dolan; C-H Pui; M V Relling
Journal:  Clin Pharmacol Ther       Date:  2008-05-28       Impact factor: 6.875

7.  Therapy-related, mixed-lineage leukaemia translocation-positive, monoblastic myeloid sarcoma of the uterus.

Authors:  Vinod Pullarkat; Leslie Veliz; Karen Chang; Ann Mohrbacher; Anna Lizza Teotico; Stephen J Forman; Marilyn L Slovak
Journal:  J Clin Pathol       Date:  2007-05       Impact factor: 3.411

Review 8.  DNA topoisomerase II, genotoxicity, and cancer.

Authors:  A Kathleen McClendon; Neil Osheroff
Journal:  Mutat Res       Date:  2007-07-03       Impact factor: 2.433

9.  Novel domain combinations in proteins encoded by chimeric transcripts.

Authors:  Milana Frenkel-Morgenstern; Alfonso Valencia
Journal:  Bioinformatics       Date:  2012-06-15       Impact factor: 6.937

10.  Zebrafish brd2a and brd2b are paralogous members of the bromodomain-ET (BET) family of transcriptional coregulators that show structural and expression divergence.

Authors:  Angela J Dibenedetto; Jake B Guinto; Timothy D Ebert; Katharine J Bee; Michael M Schmidt; Todd R Jackman
Journal:  BMC Dev Biol       Date:  2008-04-10       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.